louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06015919: Effect of Dash Diet and Acupuncture on Hypertention in Postmenopausal Women
Official title: Effect of Dash Diet and Acupuncture on Hypertention in Postmenopausal Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postmenopausal Disorder
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: faculty of physical therapy
First posted: 2023-08-29
Enrollment: 45
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: dash diet and acupuncture on post menopausal hypertention
Primary purpose: TREATMENT

Brief summary: A study of effect of dash diet and acupuncture on hypertension in postmenopausal women

Detailed description: 45 of post menopausal women divided into three groups A,B,C

* Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.
* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.
* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs.

Eligibility criteria: Inclusion Criteria:

* Their body mass index will be ranged from 25 -29.9 kg/m2
* All patients will be medically stable when attending the study.
* The DASH eating plan of 1800 kcal per day will be used in the study.

Exclusion Criteria:

* Auditory and visual problems.
* Chronic renal failure.
* Myocardial infarction or arrythmias with heart failure.

Primary outcomes:
measure: blood pressure
timeFrame: 3 months
Secondary outcomes:
measure: sodium and potassium levels
timeFrame: 3 months
Other outcomes:
measure: assessment of quality of life
timeFrame: 3 months
Locations:
city: Abu hammad
country: Egypt
facility: Alaa Nabil Elsayed Mohamed
state: Elsharqia
Study officials:
References:
Clinical trial NCT01692119: Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure
Official title: Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure (PHARM-CHF): A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Heart Failure
Keywords: chronic heart failure
medication adherence
pharmacy
interdisciplinary care
randomized controlled trial
mortality
hospitalization
Lead sponsor: Federal Union of German Associations of Pharmacists
Sponsor class: OTHER
Collaborators: name: Universität des Saarlandes
First posted: 2012-09-25
Enrollment: 258
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of the study is to investigate whether a continuous interdisciplinary intervention improves medication adherence (primary efficacy endpoint) and leads to a reduction of hospitalizations and mortality (primary safety endpoint) in elderly patients with chronic heart failure. The intervention, consisting of regular contacts with the local pharmacy and weekly dosing aids, aims to improve medication adherence and management.


Eligibility criteria: Inclusion Criteria:

* Age: 60 years and older
* Chronic heart failure (CHF)
* Stable CHF medication including a diuretic
* Hospitalization for decompensated heart failure within past 12 months OR a value of ≥ 350 pg/mL for BNP or ≥ 1,400 pg/mL for NT-proBNP
* Written informed consent

Exclusion Criteria:

* Use of a weekly dosing aid
* Unwillingness or inability to visit a participating pharmacy once a week
* Planned cardiac surgery
* Life-expectancy \< 6 months
* Unwillingness or inability to comply with the study protocol (including drug abuse or alcohol dependency)
* Participation in other studies (currently or in the last 4 weeks)

Primary outcomes:
measure: Medication Adherence
timeFrame: 12 months
measure: Days Lost Due to Unplanned Cardiovascular Hospitalizations or Death of Any Cause
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Homburg/Saar
country: Germany
facility: Saarland University
Study officials:
affiliation: Federal Union of German Associations of Pharmacists
name: Martin Schulz, Prof. PhD
role: STUDY_CHAIR
affiliation: Universitätsklinikum Leipzig
name: Ulrich Laufs, Prof. MD
role: STUDY_CHAIR
References:
citation: Laufs U, Griese-Mammen N, Krueger K, Wachter A, Anker SD, Koehler F, Rettig-Ewen V, Botermann L, Strauch D, Trenk D, Bohm M, Schulz M. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study. Eur J Heart Fail. 2018 Sep;20(9):1350-1359. doi: 10.1002/ejhf.1213. Epub 2018 May 30.
Clinical trial NCT04718519: Migrant Workers' Responses to the COVID-19 Pandemic
Official title: Responses of International Migrant Workers to Large-Scale Dormitory Outbreaks of COVID-19: A Population Survey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronavirus
Trust
Misinformation
Keywords: Migrant workers
Singapore
Vulnerable
Trust
Rumours
Resilience
Lead sponsor: Yale-NUS College
Sponsor class: OTHER
First posted: 2021-01-22
Enrollment: 1011
Sex: MALE
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consist of male migrant workers employed in manual labor jobs within Singapore

Brief summary: Rumors circulate widely during public health crises and have deleterious consequences. In this study, we seek to document the base rates of migrant workers' rumor exposure and identify predictors of rumor hearing, sharing and belief.

Detailed description: Rumors circulate widely during public health crises and have deleterious consequences. Vulnerable populations such as migrant workers tend to lack access to accurate health information, which can put them at higher risk for receiving and spreading misinformation.

In this study, we seek to document (i) the base rates of migrant workers' rumor exposure and (ii) identify predictors of rumor hearing, sharing and belief. These predictors include trust in institutions, risk perceptions, online habits and socio-demographic variables.

Data was taken from the COVID-19 Migrant Health Study, a cross-sectional study of male migrants employed in manual labor jobs within Singapore.

Eligibility criteria: Inclusion Criteria:

* At least 21 years old
* Holds a government work permit identifying their employment status

Exclusion Criteria:

* NIL

Primary outcomes:
measure: Confidence in government
timeFrame: baseline
measure: Fear for health
timeFrame: baseline
measure: Fear for job
timeFrame: baseline
measure: Degree of exposure to rumours
timeFrame: baseline
measure: Online habits
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Yale NUS
Study officials:
References:
Clinical trial NCT06577519: Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Official title: Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Lead sponsor: Jiangsu vcare pharmaceutical technology co., LTD
Sponsor class: INDUSTRY
First posted: 2024-08-29
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.


Eligibility criteria: Inclusion Criteria:

* Patients between 18 and 80 years old, with no gender restrictions.
* Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
* Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.

Exclusion Criteria:

* Expected survival time\<12 months;
* Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis;
* Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
* The researchers determined that other reasons were not suitable for participants in this experiment.

Primary outcomes:
measure: The incidence of MACE
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Shenyang
country: China
facility: General Hospital of Northern Theater Command of Chinese PLA
state: Liaoning
Study officials:
References:
Clinical trial NCT04569019: Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of Medical University of Warsaw
Official title: Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of the University Clinical Center of the Medical University of Warsaw
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vaccnation in HCW
Keywords: Medicine Vaccinations among healthcare professionals ,Vaccinations against influenza ,COVID19 pandemic and its impact on influenza vaccination coverage
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
First posted: 2020-09-29
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study will be conducted among UCKWUM healthcare professionals, i.e. doctors, nurses, paramedics, laboratory workers, pharmacists, and administration workers. Based on previous research, the group should include at least 200 participants

Brief summary: The study will be conducted in the UCKWUM teaching hospital in Warsaw between 2020 and 2022. The study group will be comprised of UCKWUM healthcare professionals All employees willing to participate in the study will receive an anonymous questionnaire on attitudes towards influenza vaccination . We will distribute information posters of the National Programme for Combating Influenza as part of the educational programme. In order to increase the effectiveness of the educational campaign, we will also send information e-mails, using the internal hospital e-mail system and conduct a series of online training courses to present the latest international reports on influenza vaccinations among health care professionals \[CITATION Abr10 \\l 1045\].

Considering the fact that lack of time \[CITATION Kus11 \\l 1045\] is the most common reason for not getting vaccinated against influenza among healthcare professionals, we will provide this group with an opportunity to receive free influenza vaccination during working hours at the UCKWUM hospital. Information about the possibility of vaccination will be provided in the form of e-mails (mailings) to hospital employees (internal hospital e-mail system), letters of information submitted to the offices of individual departments, and information posters.

The effectiveness of the educational programme will be assessed by re-administering the anonymous questionnaires after the influenza season, also by means of internal hospital e-mail system.


Eligibility criteria: Inclusion Criteria:

* Health Care worker of UCK WUM in Warsaw

Exclusion Criteria:

* non

Primary outcomes:
measure: Assesment of vaccination indeks in the hsopital by using questionare
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Warsaw Medical Uniwerity
Study officials:
References:
Clinical trial NCT00381719: Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetic Neuropathy, Painful
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2006-09-28
Enrollment: 330
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy


Eligibility criteria: Inclusion Criteria:

* Diagnosis of diabetic peripheral neuropathy
* Moderate to severe neuropathic pain

Exclusion Criteria:

* Any other uncontrolled disease
* Pregnant or nursing females

Primary outcomes:
measure: Reduction in Daily Pain Score
timeFrame: 1 Month
Secondary outcomes:
measure: Changes in sleep interference score
timeFrame: Week 4
measure: Beck depression inventory
timeFrame: Week 4
measure: Quality of Life questionnaires
timeFrame: Week 4
Other outcomes:
Locations:
city: Tacoma
country: United States
state: Washington
Study officials:
References:
Clinical trial NCT04535219: Effect of Total Sleep Deprivation on Vascular Function
Official title: Effect of Total Sleep Deprivation on Vascular Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Deprivation
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2020-09-01
Enrollment: 23
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Insufficient sleep is associated with an increased risk for cardiovascular disease. The causal mechanisms are currently unknown, but may include endothelial dysfunction. The purpose of this study is to examine the influence of sex and aging on the effects of total sleep deprivation on vascular function and whether exercise training attenuates these effects.


Eligibility criteria: Inclusion criteria:

* Males and females
* 20 to 30 and 50 to 60 years of age
* Females will be eumenorrheic at enrollment or postmenopausal for at least 1 year
* No major clinical disease (e.g., diabetes, cardiovascular, liver or chronic kidney disease) to minimize confounding of vascular measures
* Participants will be sedentary (≤3x per week of ≤30 minutes of aerobic exercise/session) or trained (≥5x per week of moderate/vigorous aerobic exercise training)

Exclusion criteria:

* Age \<20 or 31 to 49 or \>60 years
* Body mass index ≥30 kg/m\^2 because obesity may affect vascular function
* Use of medication that may affect vascular measures
* Hormone replacement therapy or hormonal contraceptives within past year
* Use of tobacco products (chewing tobacco, traditional or e-cigarettes) because they may influence vascular function
* Being perimenopausal, pregnant or lactating because may influence vascular function
* Being a shift worker because habitual sleep deprivation and altered circadian rhythm may influence vascular function.
* Not having an "intermediate" chronotype based on the Morningness-Eveningness Questionnaire (MEQ; score \<31 or \>69) because this would influence the effect of overnight sleep deprivation on vascular function.
* Sleep complaints based on the Pittsburgh Sleep Quality Index (PSQI; score \>5) because this would influence the effect of overnight sleep deprivation on vascular function.

Primary outcomes:
measure: Endothelial function
timeFrame: through study completion, an average of 1 month
measure: Microvascular function
timeFrame: through study completion, an average of 1 month
Secondary outcomes:
measure: Central arterial stiffness
timeFrame: through study completion, an average of 1 month
measure: Central arterial hemodynamics
timeFrame: through study completion, an average of 1 month
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Demetra Christou, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06564519: Resident Posture Biofeedback Study
Official title: Check Yourself Before You Wreck Yourself: A Wearable Biofeedback Device to Decrease Surgical Resident's Time in a Non-upright Posture and Work-related Musculoskeletal Pain
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Postural; Strain
Healthy
Keywords: Biofeedback
Surgery
Surgical Resident
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2024-08-21
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: While a majority of surgical ergonomic studies have been evaluating attending surgeons, few have evaluated surgical ergonomics within the surgical resident. Biofeedback devices can be partnered with education and geared towards surgical residents to decrease current and future musculoskeletal disorders, which may in turn lead to longer and more fulfilling careers.

Detailed description: This study aims to use a commercially-available posture training device for surgical residents that sends biofeedback in the form of a gentle vibration if posture has deviated from the upright (neutral) position for a long period of time. For residents performing minimally-invasive procedures with a laparoscopic approach, our overarching hypothesis is that the time spent in a non-upright position will be less after using the posture biofeedback device compared with before. The study hypothesizes that residents will report fewer complaints related to musculoskeletal pain after wearing the posture training device.

Residents completing general surgery rotations will be recruited and wear a biofeedback device for about four weeks while performing laparoscopic procedures. Posture data from the device and survey data in the form of the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) will be collected and analyzed.

Eligibility criteria: Inclusion Criteria:

* Surgical residents with surgical experience of at least one year (Postgraduate year 2-5)
* Completing a one-month rotation at the study sites within the general surgery department during the study period

Exclusion Criteria:

* Clinically diagnosed inflammatory musculoskeletal disorders per self-report
* History of orthopedic surgery in the last six months per self-report

Primary outcomes:
measure: Time spent in upright vs non-upright position
timeFrame: week 1 to week 4]
Secondary outcomes:
measure: Change in Self-reported musculoskeletal pain score
timeFrame: baseline to week 4
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: William Sherrill, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01991119: Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Official title: Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
Propafenone
Dronedarone
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the purpose of this study is to compare the ability of propafenone and dronedarone to maintain sinus rhythm after DC cardioversion

Detailed description: Atrial fibrillation is the most common arrhythmia requiring continuous therapy. Conversion to and maintenance of sinus rhythm is important. Propafenone and dronedarone has been used as treatment for maintenance of sinus rhythm after DC cardioversion. But there are no direct comparison study.

The purpose of this study is to compare the ability of propafenone and dronedarone to maintain sinus rhythm after DC cardioversion.

Eligibility criteria: Inclusion Criteria:

* a patient with persistent atrial fibrillation who received successful DC cardioversion

Exclusion Criteria:

* prior amiodarone use
* NYHA class III or IV heart failure
* Left ventricular ejection fraction \< 35%
* second or third AV block
* sick sinus syndrome
* heart rate \< 50 beat per minute
* myocardiac infarction within 3 months
* pregnant women
* severe hepatic dysfunction
* QT prolongation \> 500ms or PR interval \> 180ms
* history of hypersensitivity for drug

Primary outcomes:
measure: recurrence of atrial fibrillation
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Cardiac and Vascular Center
Study officials:
affiliation: Samsung Medical Center
name: Young Keun On, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chun KJ, Byeon K, Im SI, Park KM, Park SJ, Kim JS, On YK. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clin Ther. 2014 Sep 1;36(9):1169-75. doi: 10.1016/j.clinthera.2014.07.013. Epub 2014 Aug 16.
Clinical trial NCT06356519: Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
Official title: Effectiveness and Safety of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer: A Multi-center Real-world Retrospective Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Breast Cancer
Keywords: Sacituzumab Govitecan
breast cancer
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2024-04-10
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged over 18 years old with metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.

Brief summary: The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.


Eligibility criteria: Inclusion Criteria:

1. Patients aged over 18 years old.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. Plan to receive or has received Sacituzumab Govitecan monotherapy
4. Available medical history.

Exclusion Criteria:

1. Incomplete medical history.
2. Pregnancy or breast-breeding

Primary outcomes:
measure: PFS
timeFrame: 6 weeks
Secondary outcomes:
measure: ORR
timeFrame: 6 weeks
measure: OS
timeFrame: 6 weeks
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
affiliation: Fudan University
name: Biyun Wang, Professor
role: PRINCIPAL_INVESTIGATOR
References: